JP2016539119A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539119A5
JP2016539119A5 JP2016533172A JP2016533172A JP2016539119A5 JP 2016539119 A5 JP2016539119 A5 JP 2016539119A5 JP 2016533172 A JP2016533172 A JP 2016533172A JP 2016533172 A JP2016533172 A JP 2016533172A JP 2016539119 A5 JP2016539119 A5 JP 2016539119A5
Authority
JP
Japan
Prior art keywords
use according
probiotic composition
composition
treatment
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016533172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539119A (ja
JP6662775B2 (ja
Filing date
Publication date
Priority claimed from EP13306597.9A external-priority patent/EP2876167A1/en
Application filed filed Critical
Publication of JP2016539119A publication Critical patent/JP2016539119A/ja
Publication of JP2016539119A5 publication Critical patent/JP2016539119A5/ja
Application granted granted Critical
Publication of JP6662775B2 publication Critical patent/JP6662775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016533172A 2013-11-21 2014-11-21 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター(プレ、プロ又はシンバイオティクス)の使用 Active JP6662775B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907076P 2013-11-21 2013-11-21
EP13306597.9A EP2876167A1 (en) 2013-11-21 2013-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US61/907,076 2013-11-21
EP13306597.9 2013-11-21
PCT/IB2014/066249 WO2015075688A1 (en) 2013-11-21 2014-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019221925A Division JP2020050664A (ja) 2013-11-21 2019-12-09 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター(プレ、プロ又はシンバイオティクス)の使用

Publications (3)

Publication Number Publication Date
JP2016539119A JP2016539119A (ja) 2016-12-15
JP2016539119A5 true JP2016539119A5 (cg-RX-API-DMAC7.html) 2017-12-28
JP6662775B2 JP6662775B2 (ja) 2020-03-11

Family

ID=49680948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016533172A Active JP6662775B2 (ja) 2013-11-21 2014-11-21 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター(プレ、プロ又はシンバイオティクス)の使用
JP2019221925A Pending JP2020050664A (ja) 2013-11-21 2019-12-09 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター(プレ、プロ又はシンバイオティクス)の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019221925A Pending JP2020050664A (ja) 2013-11-21 2019-12-09 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター(プレ、プロ又はシンバイオティクス)の使用

Country Status (13)

Country Link
US (2) US10646521B2 (cg-RX-API-DMAC7.html)
EP (2) EP2876167A1 (cg-RX-API-DMAC7.html)
JP (2) JP6662775B2 (cg-RX-API-DMAC7.html)
KR (1) KR102464342B1 (cg-RX-API-DMAC7.html)
CN (1) CN106170557B (cg-RX-API-DMAC7.html)
AU (1) AU2014351348B2 (cg-RX-API-DMAC7.html)
CA (1) CA2931363C (cg-RX-API-DMAC7.html)
DK (1) DK3071709T3 (cg-RX-API-DMAC7.html)
ES (1) ES2764282T3 (cg-RX-API-DMAC7.html)
IL (2) IL245751B (cg-RX-API-DMAC7.html)
PT (1) PT3071709T (cg-RX-API-DMAC7.html)
SG (1) SG10201803877YA (cg-RX-API-DMAC7.html)
WO (1) WO2015075688A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291679B1 (en) 2015-05-06 2021-12-15 SNIPR Technologies Limited Altering microbial populations & modifying microbiota
KR102661603B1 (ko) * 2015-06-01 2024-04-29 더 유니버서티 오브 시카고 공생 미생물총의 조작에 의한 암의 치료
EP3130680A1 (en) 2015-08-11 2017-02-15 Universitat de Girona Method for the detection, follow up and/or classification of intestinal diseases
EP3365370A1 (en) 2015-10-21 2018-08-29 OSE Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
SI3209310T1 (en) * 2015-11-20 2018-06-29 4D Pharma Research Limited Compositions containing bacterial strains
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN106011281B (zh) * 2016-07-19 2019-04-23 浙江大学 肠道分节丝状菌鞭毛蛋白的检测方法
CA3036994A1 (en) * 2016-09-16 2018-03-22 uBiome, Inc. Method and system for panel characterizations
BR112019006041A2 (pt) * 2016-09-27 2019-09-03 Board Of Regents, The University Of Texas System métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
US11684640B2 (en) 2016-12-22 2023-06-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-based
US11723935B2 (en) 2017-02-06 2023-08-15 New York University Methods and compositions for treating and diagnosing pancreatic cancers
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
CN111356464A (zh) 2017-07-05 2020-06-30 伊夫罗生物科学公司 使用动物双歧杆菌乳亚种治疗癌症的组合物及方法
WO2019030411A1 (en) * 2017-08-10 2019-02-14 4D Pharma Research Limited COMPOSITIONS COMPRISING BACTERIAL STRAINS
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
CN107904298A (zh) * 2017-12-29 2018-04-13 苏州普瑞森基因科技有限公司 一种用于分析肠道微生物的试剂盒及其应用
EP3505177A1 (en) * 2017-12-29 2019-07-03 Institut Gustave Roussy Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer
EP3749751A4 (en) * 2018-02-09 2022-02-23 Keio University COMPOSITIONS AND METHODS FOR INDUCING CD8+ T LYMPHOCYTES
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
AU2019317986A1 (en) * 2018-08-05 2021-02-11 Da Volterra Method for improving anticancer agent efficacy
US11331269B2 (en) * 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
EP3629023A1 (en) * 2018-09-28 2020-04-01 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
EP4369356A3 (en) * 2018-11-30 2024-07-24 Caris MPI, Inc. Next-generation molecular profiling
CN113166815B (zh) * 2019-02-22 2024-06-11 深圳华大生命科学研究院 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
WO2020197362A1 (ko) * 2019-03-28 2020-10-01 주식회사 천랩 패칼리박테리움속 미생물 및 이를 포함하는 항암 조성물
CN111991427A (zh) * 2019-05-07 2020-11-27 瑞微(深圳)生物科技有限公司 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用
WO2020223770A1 (en) * 2019-05-08 2020-11-12 Garvan Institute Of Medical Research Cancer stratification and treatment based on inhibition of nod-2
MX2022005157A (es) * 2019-11-01 2022-08-31 Uti Lp Aprovechamiento de la energia de la microbiota y los metabolitos para el tratamiento del cancer.
WO2021102510A1 (en) * 2019-11-26 2021-06-03 South Australian Health And Medical Research Institute Limited Methods and products for reducing side effects associated with use of immune agonist antibodies
CA3163319A1 (en) * 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
CN114832088A (zh) * 2022-05-19 2022-08-02 李臻 拉瑞唑来多肽在制备缓解阿霉素心脏毒性药物中的用途
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116287355A (zh) * 2023-05-12 2023-06-23 中国医学科学院北京协和医院 上消化道肿瘤化疗疗效及不良反应的肠道菌群预测模型
CN117237952B (zh) * 2023-11-15 2024-02-09 山东大学 基于免疫地形图的染色病理切片细胞分布标注方法及系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08295631A (ja) 1995-02-27 1996-11-12 Nichinichi Seiyaku Kk 制癌増強剤
JPH1029946A (ja) * 1996-07-15 1998-02-03 Nichinichi Seiyaku Kk 液性免疫回復剤
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
RU2011115184A (ru) * 2008-09-19 2012-10-27 Нестек С.А. (Ch) Питательная поддержка для предупреждения или ослабления паралича костного мозга или нейтропении во время противораковой терапии
CA2736774C (en) 2008-09-19 2017-08-22 Institut Curie Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor
JP5717116B2 (ja) * 2008-12-22 2015-05-13 学校法人昭和大学 抗原特異的ヒトTh17細胞を調整する方法
WO2011131472A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

Similar Documents

Publication Publication Date Title
JP2016539119A5 (cg-RX-API-DMAC7.html)
FI3468573T3 (fi) Clostridium difficile -infektion hoito
JP2019001815A5 (cg-RX-API-DMAC7.html)
NZ745678A (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
JP2018199695A5 (cg-RX-API-DMAC7.html)
WO2018013583A3 (en) Medicinal vaginal lactobacillus cocktail
JP2014158488A5 (cg-RX-API-DMAC7.html)
WO2016081518A3 (en) Engineered gamma delta t-cells
HK1252759A1 (zh) 肽寡核苷酸缀合物
EP4417261A3 (en) Bacteriotherapy
JP2016501013A5 (cg-RX-API-DMAC7.html)
NZ713423A (en) Bacteriophage therapy
HK1205939A1 (en) Parenteral formulations for administering macrolide antibiotics
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2020513780A5 (cg-RX-API-DMAC7.html)
RU2018139656A (ru) Бифидобактерии для снижения потребления пищи, энергии и/или жиров
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
SG10201901391RA (en) Induction of il-12 using immunotherapy
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
ATE536102T1 (de) Probiotischer stamm von lactobacillus delbrueckii subsp bulgaricus
RU2008129232A (ru) Способ лечения туберкулеза легких у больных вич-инфекцией
Srikanth et al. Enhanced regression of tumors in mice with combined chemotherapy and immunotherapy
Na et al. Protective effect of Ginsan against Vibrio vulnificus infection
JP2007538066A5 (cg-RX-API-DMAC7.html)
Jackson Problems and prospects of creation medical preparations based on copyright bacteria